{
    "name": "triamcinolone acetonide extended-release injectable suspension",
    "comment": "Rx",
    "other_names": [
        "Zilretta"
    ],
    "classes": [
        "Corticosteroids"
    ],
    "source": "https://reference.medscape.com/drug/Zilretta-triamcinolone-acetonide-extended-release-injectable-suspension-1000219",
    "pregnancy": {
        "common": [
            "There are no data regarding the use in pregnant women to inform a drug associated risk of adverse developmental outcomes",
            "In animal reproductive studies from published literature, pregnant mice, rats, rabbits, or primates administered triamcinolone acetonide during organogenesis period at doses that produced exposures less than the maximum recommended human dose (MRHD) caused resorptions, decreased fetal body weight, craniofacial and/or other abnormalities such as omphalocele",
            "Corticosteroids may result in menstrual pattern irregularities (eg, deviations in timing, duration of menses, increased/decreased blood loss)"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no available data on the presence of triamcinolone acetonide in either human or animal milk, the effects on the breastfed infant, or the effects on milk production",
            "Corticosteroids have been detected in human milk and may suppress milk production",
            "Caution should be exercised when metabolic-endocrine#corticosteroids are administered to breastfeeding women"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Triamcinolone acetonide extended-release injectable suspension is for intra-articular use only, not for IV, IM, SC, intradermal, intraocular, epidural, intraocular, or intrathecal (IT) use",
                "Instances of anaphylaxis reported in patients with hypersensitivity to metabolic-endocrine#corticosteroids; cases of serious anaphylaxis, including death, reported in individuals receiving triamcinolone acetonide injection, regardless of route of administration; institute appropriate care upon occurrence of an anaphylactic reaction",
                "Rare instances of anaphylaxis have been reported in individuals receiving triamcinolone acetonide injection, regardless of the route of administration (see Contraindications)",
                "Corticosteroids can produce reversible hypothalamic-pituitary-adrenal axis suppression, potential for adrenal sufficiency after withdrawal of treatment, which may persist for months; institute corticosteroid replacement therapy in situations of stress (eg, stress) during that period",
                "Corticosteroids may increase blood pressure, salt and water retention, and potassium and calcium excretion; monitor for signs or symptoms (eg, edema, weight gain, and imbalance in serum electrolytes) in congestive heart failure or hypertensive patients",
                "Corticosteroid may be associated with development or exacerbation of increased intraocular pressure; monitor patients with elevated intraocular pressure for potential treatment adjustment",
                "Increased risk of gastrointestinal perforation with certain GI disorders (eg, active or latent peptic ulcers, diverticulosis, diverticulitis, ulcerative colitis, fresh intestinal anastomoses); avoid metabolic-endocrine#corticosteroids in these patients because signs of peritoneal irritation following gastrointestinal perforation may be minimal or absent",
                "Corticosteroids decrease bone formation and increase bone resorption through their effect on calcium regulation and inhibition of osteoblast function; give special consideration to patients with or at increased risk of osteoporosis (eg, postmenopausal women) before initiating corticosteroid therapy",
                "Risk of behavioral and mood disturbances may be associated with corticosteroid use; advise patients and/or caregivers to immediately report any new or worsening behavior or mood disturbances; give special consideration to patients with previous or current emotional instability or psychiatric illness before initiating corticosteroid therapy"
            ],
            "specific": [
                {
                    "type": "Infections",
                    "description": [
                        "Intra-articular injection of corticosteroid may be complicated by joint infection; avoid injection into an infected site; intra-articular infection may result in damage to joint tissues",
                        "Intra-articularly injected metabolic-endocrine#corticosteroids are systemically absorbed; patients taking metabolic-endocrine#corticosteroids are more susceptible to infections than are healthy individuals",
                        "A marked increase in pain accompanied by local swelling, further restriction of joint motion, fever, and malaise are suggestive of septic arthritis; if this complication occurs and a diagnosis of septic arthritis is confirmed, institute appropriate antimicrobial therapy",
                        "Local injection of a corticosteroid into a previously infected joint is not usually recommended; examine any joint fluid present to exclude a septic process",
                        "Intra-articularly injected metabolic-endocrine#corticosteroids are systemically absorbed; in patient treated with metabolic-endocrine#corticosteroids, there may be decreased resistance and inability to localize infection when metabolic-endocrine#corticosteroids are used",
                        "Infection with any pathogen (viral, bacterial, fungal, protozoan, or helminthic) in any location of the body may be associated with use of metabolic-endocrine#corticosteroids alone or in combination with other immunosuppressive agents; these infections may be mild to severe",
                        "With increasing doses of metabolic-endocrine#corticosteroids, the rate of occurrence of infectious complications increases; metabolic-endocrine#corticosteroids may also mask some signs of current infection",
                        "Advise patients to inform their health care provider if they develop fever or other signs or symptoms of infection; advise patients who have not been vaccinated to avoid exposure to chicken pox or measles; instruct patients to contact their health care provider immediately if they are exposed"
                    ]
                },
                {
                    "type": "Serious neurologic adverse events with epidural or IT injection",
                    "description": [
                        "Serious neurologic events, some resulting in death, have been reported with epidural or IT injection",
                        "Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke",
                        "These serious neurologic events have been reported with and without use of fluoroscopy",
                        "Safety and effectiveness of epidural administration of metabolic-endocrine#corticosteroids have not been established, and metabolic-endocrine#corticosteroids are not approved for this use"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression",
                        "Concomitant with potassium-depleting agents (ie, amphotericin B, diuretics), observe for development of hypokalemia",
                        "Cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure",
                        "Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance",
                        "Concomitant use of anticholinesterase agents and metabolic-endocrine#corticosteroids may produce severe weakness in patients with myasthenia gravis; if possible, withdraw anticholinesterase agents at least 24 hours before initiating corticosteroid therapy",
                        "Coadministration of metabolic-endocrine#corticosteroids and warfarin usually results in inhibition of response to warfarin; monitor INR",
                        "Corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required",
                        "Corticosteroids may decrease isoniazid serum concentrations",
                        "Cholestyramine may increase corticosteroid clearance",
                        "Increased activity of both cyclosporine and metabolic-endocrine#corticosteroids may occur when the 2 are used concurrently; convulsions have been reported with this concurrent use",
                        "Estrogens may decrease the hepatic metabolism of certain metabolic-endocrine#corticosteroids, thereby increasing their effect",
                        "Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia",
                        "Corticosteroids may suppress reactions to allergy related skin tests",
                        "Aspirin and NSAIDs",
                        "Coadministration of aspirin (or other NSAIDs) and metabolic-endocrine#corticosteroids increases risk of gastrointestinal side effects Use this combination cautiously in hypoprothrombinemia",
                        "Salicylate clearance may be increased if coadministered with metabolic-endocrine#corticosteroids",
                        "CYP3A4 inducers/inhibitors",
                        "Concomitant use with CYP3A4 inducers may enhance the metabolism of metabolic-endocrine#corticosteroids and may require an increase in the corticosteroid dose",
                        "Ketoconazole, a strong CYP3A4 inhibitor, has been reported to decrease the metabolism of certain metabolic-endocrine#corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects"
                    ]
                },
                {
                    "type": "Vaccines",
                    "description": [
                        "Prolonged corticosteroid therapy may cause a diminished response to toxoids, live, or inactivated vaccines due to inhibition of antibody response; possibly potentiate the replication of some organisms contained in live attenuated vaccines",
                        "If possible, defer routine administration of vaccines or toxoids until corticosteroid therapy is discontinued"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid prophylactic use of systemic corticosteroids as premedication before CAR-T cell therapy. Corticosteroids may, however, be required for treatment of cytokine release syndrome or neurologic toxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension, cyclosporine. Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may increase or decrease cyclosporine concentrations. Also, cyclosporine may increase the plasma concentrations of the corticosteroids. Monitor for changes in cyclosporine concentrations and for toxicities of corticosteroids and/or cyclosporine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine and triamcinolone acetonide extended-release injectable suspension both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lonapegsomatropin",
            "description": {
                "common": "lonapegsomatropin decreases effects of triamcinolone acetonide extended-release injectable suspension by Other (see comment). Use Caution/Monitor. \nComment: Growth hormone (GH) inhibits microsomal enzyme 11 beta-hydroxysteroid dehydrogenase type 1, which converts cortisone to its active metabolite, cortisol. Patients with untreated GH deficiency may have increases in serum cortisol, and initiation of lonapegsomatropin may result decreased serum cortisol. Patients with hypoadrenalism treated with glucocorticoids may require an increase glucocorticoid stress or maintenance doses following lonapegsomatropin initiation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, triamcinolone acetonide extended-release injectable suspension.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin and triamcinolone acetonide extended-release injectable suspension both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Use of oxaliplatin with concomitant immunosuppressants or with impaired immune systems may increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod, triamcinolone acetonide extended-release injectable suspension.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration with immunosuppressive therapies may increase the risk of additive immune effects during therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs in order to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and triamcinolone acetonide extended-release injectable suspension both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of triamcinolone acetonide extended-release injectable suspension by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of triamcinolone acetonide extended-release injectable suspension by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "somapacitan",
            "description": {
                "common": "somapacitan decreases effects of triamcinolone acetonide extended-release injectable suspension by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Microsomal enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) required for cortisone conversion to its active metabolite, cortisol, in hepatic and adipose tissue. GH inhibits 11-beta-HSD-1. Patients treated with glucocorticoid for hypoadrenalism may require increased maintenance or stress doses after initiating somapacitan."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, triamcinolone acetonide extended-release injectable suspension.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, triamcinolone acetonide extended-release injectable suspension.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and triamcinolone acetonide extended-release injectable suspension both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "triamcinolone acetonide extended-release injectable suspension increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Joint swelling",
            "percent": "3"
        },
        {
            "name": "Contusion",
            "percent": "2"
        },
        {
            "name": "Sinusitis",
            "percent": "2"
        },
        {
            "name": "Cough",
            "percent": "2"
        },
        {
            "name": "Contusions",
            "percent": "2"
        },
        {
            "name": "Endocrine",
            "percent": null
        },
        {
            "name": "Increased blood glucose",
            "percent": null
        },
        {
            "name": "in diabetic patients",
            "percent": null
        },
        {
            "name": "General and administration site conditions",
            "percent": null
        },
        {
            "name": "Pain including injection site pain or discomfort and leg pain",
            "percent": null
        },
        {
            "name": "Immune system",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions including pruritis",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "and anaphylaxis",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Septic arthritis",
            "percent": null
        },
        {
            "name": "Musculoskeletal",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "joint swelling or effusion",
            "percent": null
        },
        {
            "name": "muscle spasms",
            "percent": null
        },
        {
            "name": "Nervous system",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Reproductive system",
            "percent": null
        },
        {
            "name": "Postmenopausal vaginal bleeding",
            "percent": null
        },
        {
            "name": "similar to a menstrual period",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue",
            "percent": null
        },
        {
            "name": "Pruritis",
            "percent": null
        }
    ]
}